|
|
|
| Effect of miR21 on cisplatin chemosensitivity of cervical cancer Hela cells and cisplatin-resistant Hela/DDP cells |
| YUE Xiaoxue1 MIAO Jinwei2 LU Pan1 |
1.The Medicine Department of Obstetrics and Gynecology, Capital Medical University, Beijing 100069, China;
2.Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100006, China |
|
|
|
Abstract Objective To detect the influence of miR21 gene expression on the sensitivity of cervical cancer Hela cells and cisplatin-resistant Hela/DDP cells to cisplatin. Methods Mature miR21 mimic, inhibitor and negative control (NC) miRNA were transfected into Hela and Hela/DDP cells by riboFECTTM CP. Hela cells were divided into mimic group, NC group and Blank group and Hela/DDP were divided into inhibitor group, NC group and Blank group. Real-time PCR was used to measure the expression of miR21 in each group. MTT was used to detect the half inhibitory concentration (IC50) of cisplatin. Results ①Real-time PCR results showed that the expression of miR21 was an average of (5.452±0.074) fold higher in Hela/DDP than in Hela (P < 0.01). The expression of miR21 in mimic group was obviously higher than those in NC and Blank groups (P < 0.01). The expression of miR21 in inhibitor group was significantly lower than those in NC and Blank groups (P < 0.01). There was no statistical difference between NC group and Blank group in Hela and Hela/DDP cells (P ＞ 0.05). ②MTT results showed that the sensitivity of Hela to cisplat in decreased after mimic transfection while the Hela/DDP increased after transfected with inhibitor (P < 0.05). There was no significant difference between NC group and Blank group (P ＞ 0.05). Conclusion ①The expression of miR21 is upregulated in Hela/DDP cells, while it wis down regulated in Hela cells. ②Over expression of miR21 in Hela can reduce its sensitivity to cisplatin obviously. Inhibition of miR21 in Hela/DDP can significantly increase its sensitivity tocisplatin.
|
|
|
|
|
|
[1] Siegel R，Naishadham D，Jemal A. Cancer statistics，2012 [J]. CA Cancer J Clin，2013，63（1）：11-30.
[2] 许卫东，何合良，赵一虹，等.中晚期宫颈癌顺铂同步放化疗与单纯放疗治疗疗效比较[J].中华肿瘤防治杂志，2017，11：5456.
[3] Liu B，Pan CF，Ma T，et al. Long non-coding RNA AK0 01796 contributes to cisplatin resistance of non small cell lung cancer [J]. Mol Med Rep，2017，16（4）：4107-4112.
[4] Jang HS，Woo SR，Song KH，et al. API5 induces cisplatin resistance through FGFR signaling in human cancer cells [J]. Exp Mol Med，2017，49（9）：e374.
[5] Donzelli S，Mori F，Biagioni F，et al. MicroRNAs：short non-coding players in cancer chemoresistance [J]. Mol Cell Ther，2014，2（1）：16.
[6] Geretto M，Pulliero A，Rosano C，et al. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators [J]. Am J Cancer Res，2017，7（6）：1350.
[7] Zheng P，Li C，Yuan X，et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells [J]. J Exp Clin Cancer Res，2017，36（1）：53.
[8] Rui M，Qu Y，Gao T，et al. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells [J]. Int J Nanomedicine，2016，12：217-237.
[9] Ziyan W，Yang L. MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line [J]. Ir J Med Sci，2014，185（1）：1-7.
[10] Au Yeung CL，Co NN，Tsuruga T，et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 [J]. Nat Commun，2016，7：11 150.
[11] Li X，Qian X，Li X，et al. MicroRNA-21 regulates the proliferation and apoptosis of cervical cancer cells via tumor necrosis factor-α [J]. Mol Med Rep，2017，16（4）：4659-4663.
[12] Abue M，Yokoyama M，Shibuya R，et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer [J]. Int J Oncol，2015，46（2）：539-547.
[13] Leite KRM，Reis ST，Viana N，et al. Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer [J]. J Cancer，2015，6（3）：292-301.
[14] Danilova OV，Paiva C，Kaur P，et al. MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia [J]. Br J Haematol，2015，170（2）：272.
[15] Zheng Z，Xu PP，Wang L，et al. MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells [J]. Exp Clin Cancer Res，2017，36（1）：82.
[16] Asaga S，Kuo C，Nguyen T，et al. Direct serum assay for MicroRNA-21 Concentrations in early and advanced breast cancer [J]. Clin Chem，2011，57（1）：84.
[17] Wang ZX，Lu BB，Wang H，et al. MicroRNA-21modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN [J]. Arch Med Res，2011，42（4）：281-290.
[18] Li Y，Li W，Yang Y，et al. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme [J]. Brain Res，2009，1286（2）：13-18.
[19] Chan JK，Blansit K，Kiet T，et al. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer [J]. Gynecol Oncol，2014，132（3）：739-744.
[20] Shen H，Zhu F，Liu J，et al. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer [J]. PLoS One，2014，9（7）：e103 305. |
|
|
|
